Hosted on MSN24d
Eli Lilly in pact with Magnet Bio to develop cancer drugs in a deal worth up to $1.25BMagnet Biomedicine announced Friday it has reached a licensing agreement worth up to $1.25B with Eli Lilly (NYSE:LLY) to develop cancer drugs leveraging the company’s TrueGlue discovery platform.
Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...
One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback